Cadila Healthcare is currently trading at Rs. 404.40, up by 3.85 points or 0.96% from its previous closing of Rs. 400.55 on the BSE.
The scrip opened at Rs. 401.00 and has touched a high and low of Rs. 408.00 and Rs. 399.05 respectively. So far 87614 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 554.20 on 25-Jul-2017 and a 52 week low of Rs. 341.65 on 22-May-2018.
Last one week high and low of the scrip stood at Rs. 412.30 and Rs. 382.00respectively. The current market cap of the company is Rs. 41384.79 crore.
The promoters holding in the company stood at 74.79%, while Institutions and Non-Institutions held 16.64% and 8.40% respectively.
Zydus Cadila has received the tentative approval from the US Food and Drug Administration (USFDA) to market Tadalafil Tablets USP, 2.5 mg, 5 mg, 10 mg and 20 mg. It is used to treat erectile dysfunction (impotence) and symptoms of benign prostatic hypertrophy (enlarged prostate). It will be manufactured at the group's manufacturing facility at Moraiya, Ahmedabad.
The group now has more than 195 approvals and has so far filed over 330 ANDAs since the commencement of the filing process in FY 2003-04.
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1849.05 |
Dr. Reddys Lab | 1274.25 |
Cipla | 1553.20 |
Lupin | 2184.00 |
Zydus Lifesciences | 1001.85 |
View more.. |